Home » Newsletters » BioWorld Science

BioWorld Science

July 7, 2015

View Archived Issues

ADA highlights: ultra-long acting GLP-1/glucagon agonists for type 2 diabetes and obesity

Novel inhibitor of Plasmodium protein synthesis shows promise for malaria

Prism Pharma begins phase I/II study of C-82 topical gel

Five Prime Therapeutics begins phase I/II trial of FPA-008

Japanese team discloses Wnt signaling pathway inhibitors

Baxter spin-off Baxalta now in business

Versartis confirms removal of FDA partial hold on VRS-317 trial

Bristol-Myers Squibb patents TYK2 inhibitors

Lycera describes F1F0-ATPase inhibitors

Almirall reports JAK inhibitors

Quanticel Pharmaceuticals reports development of KDM1A inhibitors

Chong Kun Dang Holdings divulges HDAC6 inhibitors

[18F]AZC2, a novel PET probe for c-MET imaging

Scaffolds based on synthetic TCP and autologous cells for maxillofacial surgery

Strensiq receives first approval in Japan for hypophosphatasia

CAT-1004 receives FDA fast track designation for Duchenne muscular dystrophy

Novel PI3Kdelta inhibitor shows promise for the treatment of EBA

MD Anderson Cancer Center starts phase I trial of siRNA targeting EphA2

NIDA tests AZD-8529 for smoking cessation

Janssen opens daratumumab expanded access program in U.S.

FDA clears Celtaxsys to begin phase II trial of acebilustat for cystic fibrosis

Olanedine antiseptic approved in Japan

JNJ-42165279 enters phase II trial in social anxiety disorder

Ignyta collaborates with UCSF on proof-of-concept trial of entrectinib in metastatic melanoma

Celtic Biotech and Emory University agree to develop crotamine-based imaging agent

Celsion releases new interim data from DIGNITY breast cancer study of ThermoDox

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for March 10, 2026.
Cas and effect: Merck’s phase III ripples HIF-2α space
BioWorld
Oddsmakers wasted no time figuring the market chances after Merck & Co. Inc. rolled out data from the phase III Litespark-011 study testing its oral...
Brain’s hidden tau-clearing pathway uncovered
BioWorld Science
Researchers at INSERM and collaborators have identified hypothalamic tanycytes as mediators of tau clearance and shown that their structural and genetic...
News in brief
BioWorld Asia
BioWorld Asia briefs for March 10, 2026
MSD synthesizes α-synuclein PET agents
BioWorld Science
Merck Sharp & Dohme LLC (MSD) has prepared and tested new positron emission tomography (PET) agents for binding and imaging α-synuclein (SNCA) for the diagnosis...